StockData

Editas Medicine vs Prime Medicine

EDIT and PRME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EDIT and PRME compare

Prime Medicine is the larger company, worth 2.1 times as much as Editas Medicine ($780M against $366M).

Prime Medicine scores higher on the StockData Score (5 against 3 for Editas Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEDITPRME
Size and price
Market cap$366M$780M
Share price$2.38$4.30
Change, 1 year−5.6%22.0%
Change, 5 years−93.3%−79.6%
Beta (5Y)2.190.43
Employees87146
StockData Score
Total score35 (better)
Valuation score00
Growth score1 (better)0
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/S7.3×–
P/B4.3× (better)19.6×
FCF yield−30.2%−20.1% (better)
Fair value$1.62–
Margin of safety−47.2%–
Growth
Revenue growth (TTM)7.4%–
Revenue growth, 5Y average−14.9%−2.3% (better)
Profitability
Operating margin−152%–
Net margin−145%–
FCF margin−222%–
Return on equity−147% (better)−373%
Financial health
Debt / equity0.67 (better)0.00
Interest coverage−10.6×–
Current ratio2.823.05 (better)
Altman Z-score−9.39−5.56 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Buyback yield−36.6%–
Shareholder yield−36.6%0.00% (better)
Ownership
Held by institutions78.3%58.8%
Held by insiders0.45%18.6%
Insider net buying, 12 months−$107K–
Short interest, % of float25.3%19.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.